http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Abe, Hajime,Kawai, Yuki,Mori, Tsuyoshi,Tomida, Kaori,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.11
Background: Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Materials and Methods: Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 ${\mu}g/day$ B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design. Results: The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was $2.7{\pm}2.2$. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was $4.9{\pm}2.4$. Conclusions: Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.
Development of Knee Joint Robot for Students Becoming Therapist
Yoshifumi Morita,Yuki Kawai,Yusuke Hayashi,Tatsuya Hirano,Hiroyuki Ukai,Kouji Sanaka,Hironori Nakamuta,Keiko Takao 제어로봇시스템학회 2010 제어로봇시스템학회 국제학술대회 논문집 Vol.2010 No.10
The authors are developing a knee joint robot as an educational tool for students becoming physical therapist (PT) or occupational therapist (OT). The robot can simulate some problems of a knee joint, such as range of motion trouble, contracture, rigidity, spasticity and so on. The robot has a knee joint mechanism to realize not only flexion/extension movement but also inner/outer rotation movement, which is based on the idea of rolling, sliding and coming off movement. In addition the robot has the wire drive system to control the knee joint passive movement. In this paper we design optimal arrangement of four pulleys in the wire drive system by introducing performance indices. In addition we design control algorithms to imitate two kinds of knee joint troubles and verify the effectiveness by fundamental experiments.
Abe, Hajime,Mori, Tsuyoshi,Kawai, Yuki,Tomida, Kaori,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.8
Background: We compared treatment completion rates and safety of docetaxel and cyclophosphamide sixcycle therapy (TC6) with docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC) therapy in Japanese patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Materials and Methods: We administered TC6 q3w or T-FEC q3w to HER2-negative breast cancer patients. The primary endpoint of this trial was toxicity. As second endpoints, the treatment completion rate and relative dose intensity were evaluated. Results: The TC6 and T-FEC group consisted of 22 and 21 patients, respectively. Concerning hematological toxicity, grade 3 or higher adverse reactions included neutropenia and febrile neutropenia. As non-hematological adverse events, exanthema and peripheral neuropathy were frequently reported in the TC6 group, whereas more patients of the T-FEC group reported nausea and vomiting. In TC6, the treatment completion rate was 86.4% and the relative dose intensity of docetaxel was 93.2%. In T-FEC, the values were 95.2% and 98.9%, respectively. Conclusions: These results suggest that TC6 is tolerable in Japanese, and that this regimen can also be performed in outpatient clinics. However, with the TC6 regimen, the compliance was slightly lower than with the T-FEC regimen, and supportive therapy needs to be managed appropriately.
Abe, Hajime,Mori, Tsuyoshi,Kawai, Yuki,Tomida, Kaori,Yamazaki, Keiichi,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.8
Background: The infusion rate is considered to affect incidence and severity of infusion reactions (IRs) caused by protein formulations. Trastuzumab (TRS) is approved for 90-minute infusion as the initial dose followed by 30-minute infusion with 250 ml saline. In the study, we evaluated the safety of TRS intravenously administered over 30 minutes with 100 ml saline to reduce burden of patients, safety of infusion with 250 ml saline already being established. Materials and Methods: Women with HER2 positive breast cancer, ${\geq}18$ years and ${\geq}55%$ left ventricular ejection fraction (LVEF), were registered in the study. Patients received 8mg/kg of TRS 250 ml over 90 minutes followed by 6mg/kg of TRS 100ml over 30 minutes in a three-week cycle. Results: A total of 31 patients were recruited, 24 for adjuvant therapy and seven with metastases. The median age was 59 years (range 39 to 82). The total number of TRS doses ranged from 5 to 17 with the median of 15. Mild IR occurred in two patients at the first dose. However, no IR was observed after reducing to 100 ml saline. No decrease of LVEF, increase of serum brain natriuretic peptide or any other adverse events were reported. Conclusions: Intravenous infusion of TRS with 100 ml saline over 30 minutes in breast cancer patients can be considered safe based on results from the study. It can be given on an outpatient basis as with the currently recommended dilution in 250 ml saline.
INTERPRETATION OF (596) SCHEILA'S TRIPLE DUST TAILS
Ishiguro, Masateru,Hanayama, Hidekazu,Hasegawa, Sunao,Sarugaku, Yuki,Watanabe, Jun-ichi,Fujiwara, Hideaki,Terada, Hiroshi,Hsieh, Henry H.,Vaubaillon, Jeremie J.,Kawai, Nobuyuki,Yanagisawa, Kenshi,Kuro IOP Publishing 2011 ASTROPHYSICAL JOURNAL LETTERS - Vol.741 No.1
<P>Strange-looking dust cloud around asteroid (596) Scheila was discovered on 2010 December 11.44-11.47. Unlike normal cometary tails, it consisted of three tails and faded within two months. We constructed a model to reproduce the morphology of the dust cloud based on the laboratory measurement of high-velocity impacts and the dust dynamics. As a result, we succeeded in reproducing the peculiar dust cloud by an impact-driven ejecta plume consisting of an impact cone and downrange plume. Assuming an impact angle of 45 degrees, our model suggests that a decameter-sized asteroid collided with (596) Scheila from the direction of (alpha(im), delta(im)) = (60 degrees, -40 degrees) in J2000 coordinates on 2010 December 3. The maximum ejection velocity of the dust particles exceeded 100 m s(-1). Our results suggest that the surface of (596) Scheila consists of materials with low tensile strength.</P>
OBSERVATIONAL EVIDENCE FOR AN IMPACT ON THE MAIN-BELT ASTEROID (596) SCHEILA
Ishiguro, Masateru,Hanayama, Hidekazu,Hasegawa, Sunao,Sarugaku, Yuki,Watanabe, Jun-ichi,Fujiwara, Hideaki,Terada, Hiroshi,Hsieh, Henry H.,Vaubaillon, Jeremie J.,Kawai, Nobuyuki,Yanagisawa, Kenshi,Kuro IOP Publishing 2011 ASTROPHYSICAL JOURNAL LETTERS - Vol.740 No.1
<P>An unexpected outburst was observed around (596) Scheila in 2010 December. We observed (596) Scheila soon after the impact using ground-based telescopes. We succeeded in the detection of a faint linear tail after 2011 February, which provides a clue to determine the dust ejection date. It is found that the dust particles ranging from 0.1-1 mu m to 100 mu m were ejected into the interplanetary space impulsively on December 3.5 +/- 1.0 day. The ejecta mass was estimated to be (1.5-4.9) x 10(8) kg, suggesting that an equivalent mass of a 500-800 m diameter crater was excavated by the event. We also found that the shape of the light curve changed after the impact event probably because fresh material was excavated around the impact site. We conclude that a decameter-sized asteroid collided with (596) Scheila only eight days before the discovery.</P>
Alkoxysilane Compound Coating on Mortar Surfaces and Evaluation of Its Anti-biofilm Properties
Hideyuki Kanematsu,Dana M. Barry,Akiko Ogawa,Takeshi Kogo,Risa Kawai,Hidekazu Miura,Nobumitsu Hirai,Akihiro Maegawa,Yuki Murakami,Kaori Omata,Katsuhiko Tsunasima,Katsuhiko Sano,Akira Suzuki,Yoshiaki S 한국표면공학회 2023 한국표면공학회 학술발표회 초록집 Vol.2023 No.11-1
Sanuki, Takuro,Mishima, Gaku,Kurata, Shinji,Watanabe, Toshihiro,Kiriishi, Kensuke,Tachi, Mizuki,Ozaki, Yu,Okayasu, Ichiro,Kawai, Mari,Matsushita, Yuki,Miura, Keiichiro,Ayuse, Takao The Korean Dental Society of Anesthsiology 2015 Journal of Dental Anesthesia and Pain Medicine Vol.15 No.3
Background: We hypothesized that ketamine, when administered as the anesthetic induction agent, may prevent cardiovascular depression during high-dose remifentanil administration, unlike propofol. To test our hypothesis, we retrospectively compared the hemodynamic effects of ketamine, during high-dose remifentanil administration, with those of propofol. Methods: Thirty-eight patients who underwent oral surgery at the Nagasaki University Hospital between April 2014 and June 2015 were included in this study. Anesthesia was induced by the following procedure: First, high-dose remifentanil ($0.3-0.5{\mu}g/kg/min$) was administered 2-3 min before anesthesia induction;next, the anesthetic induction agent, either propofol (Group P) or ketamine (Group K), was administered. Mean arterial pressure (MAP) and the heart rate were recorded by the automated anesthesia recording system at four time points: immediately before the administration of high-dose remifentanil (T1);immediately before the administration of propofol or ketamine (T2);2.5 min (T3), and 5 min (T4) after the administration of the anesthetic induction agent. Results: In Group P, the MAP at T3 ($75.7{\pm}15.5mmHg$, P = 0.0015) and T4 ($68.3{\pm}12.5mmHg$, P < 0.001) were significantly lower than those at T1 ($94.0{\pm}12.4mmHg$). However, the MAP values in the K group were very similar (P = 0.133) at all time points. The heart rates in both Groups P (P = 0.254) and K (P = 0.859) remained unchanged over time. Conclusions: We showed that ketamine, when administered as the anesthetic induction agent during high-dose remifentanil administration, prevents cardiovascular depression.